BACKGROUND: Heterogeneity of primary tumor volume within tumors of the same classification indicates a need to elucidate the effects of primary tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC). METHODS: From 1994 through 1996, 129 patients with newly diagnosed NPC who were treated with high-dose radiotherapy were enrolled in the study. Computed tomography-derived primary tumor volume was measured using the summation-of-area technique. Correlations between American Joint Committee on Cancer (AJCC) disease stage, primary tumor volume, and disease-specific survival were assessed using a Cox regression model. Cross-validation based on receiver operating characteristic (ROC) curve also was examined. RESULTS: Compared with the AJCC staging system and the TNM classification system, primary tumor volume was better at determining cumulative survival for patients with NPC. Hazard ratios increased with tumor volume, ranging from 6.68 (95% confidence interval [95% CI], 1.89-23.67) for tumor volumes between 20-40 mL, 18.03 (95% CI, 4.80-67.75) for tumor volumes between 40-60 mL, and 26.06 (95% CI, 7.70-88.20) for tumor volumes > 60 mL. With both tumor volume and T classification in the same Cox regression model, only tumor volume remained statistically significant in the prognosis of NPC. The validation results with ROC curves also revealed that, in predicting patient outcome, primary tumor volume (area under the ROC = 83.33%) was superior to disease stage (area under the ROC = 66.53%) and TNM classification (area under the ROC = 58.61%). CONCLUSIONS: The incorporation of primary tumor volume may lead to a further refinement of the current AJCC staging system, particularly for patients with large primary tumor volumes (> 60 mL), who require more aggressive treatment. Cancer 2004. Copyright 2004 American Cancer Society.
BACKGROUND: Heterogeneity of primary tumor volume within tumors of the same classification indicates a need to elucidate the effects of primary tumor volume on treatment outcomes in patients with nasopharyngeal carcinoma (NPC). METHODS: From 1994 through 1996, 129 patients with newly diagnosed NPC who were treated with high-dose radiotherapy were enrolled in the study. Computed tomography-derived primary tumor volume was measured using the summation-of-area technique. Correlations between American Joint Committee on Cancer (AJCC) disease stage, primary tumor volume, and disease-specific survival were assessed using a Cox regression model. Cross-validation based on receiver operating characteristic (ROC) curve also was examined. RESULTS: Compared with the AJCC staging system and the TNM classification system, primary tumor volume was better at determining cumulative survival for patients with NPC. Hazard ratios increased with tumor volume, ranging from 6.68 (95% confidence interval [95% CI], 1.89-23.67) for tumor volumes between 20-40 mL, 18.03 (95% CI, 4.80-67.75) for tumor volumes between 40-60 mL, and 26.06 (95% CI, 7.70-88.20) for tumor volumes > 60 mL. With both tumor volume and T classification in the same Cox regression model, only tumor volume remained statistically significant in the prognosis of NPC. The validation results with ROC curves also revealed that, in predicting patient outcome, primary tumor volume (area under the ROC = 83.33%) was superior to disease stage (area under the ROC = 66.53%) and TNM classification (area under the ROC = 58.61%). CONCLUSIONS: The incorporation of primary tumor volume may lead to a further refinement of the current AJCC staging system, particularly for patients with large primary tumor volumes (> 60 mL), who require more aggressive treatment. Cancer 2004. Copyright 2004 American Cancer Society.
Authors: Jia-Yin Zhou; Vincent F H Chong; James B K Khoo; Kap-Luk Chan; Jing Huang Journal: Eur Arch Otorhinolaryngol Date: 2006-09-21 Impact factor: 2.503
Authors: Jing Wang; Jian Li Hu; Ru Bo Cao; Qian Ding; Gang Peng; Shi Jiang Fei; Yao Jiang; Peng Cheng Li; Kun Yu Yang; Wen Jie Zhang; Gang Wu; Ruo Zheng Wang; Pin Dong Li Journal: Oncol Lett Date: 2015-04-03 Impact factor: 2.967
Authors: Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Andreas Scorilas Journal: Mol Med Date: 2010-12-08 Impact factor: 6.354
Authors: Paul B Romesser; Muhammad M Qureshi; Rathan M Subramaniam; Osamu Sakai; Scharukh Jalisi; Minh T Truong Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339